Effects of chronic oral treatment with aripiprazole on the expression of NMDA receptor subunits and binding sites in rat brain

Psychopharmacology

Volumn 217, Issue 1, 2011, Pages 127-142

  Segnitz, Nina ^a   Ferbert, Thomas ^a   Schmitt, Andrea ^b,c   Gass, Peter ^a   Gebicke Haerter, Peter J ^a   Zink, Mathias ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Animal model; Antipsychotic; Aripiprazole; Dopamine; Glutamate; NMDA; Receptor; Schizophrenia; Serotonin

Indexed keywords

ARIPIPRAZOLE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 1; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2A; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2C; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2D;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTERIOR CINGULATE; ARTICLE; AUTORADIOGRAPHY; BINDING SITE; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DRUG ACTIVITY; DRUG EFFICACY; HIPPOCAMPUS; MALE; NEUROTRANSMISSION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; RAT; TISSUE DISTRIBUTION; TRANQUILIZING ACTIVITY;

ADMINISTRATION, ORAL; ANIMALS; ANTIPSYCHOTIC AGENTS; AUTORADIOGRAPHY; BINDING SITES; BRAIN; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION; IN SITU HYBRIDIZATION; MALE; PIPERAZINES; PROTEIN BINDING; PROTEIN SUBUNITS; QUINOLONES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, N-METHYL-D-ASPARTATE; SEROTONIN; SYNAPTIC TRANSMISSION;

EID: 82955167869     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-011-2262-z     Document Type: Article

References (106)

1. Baier PC, Blume A, Koch J, Marx A, Fritzer G, Aldenhoff JB, Schiffelholz T (2009) Early postnatal depletion of NMDA receptor development affects behaviour and NMDA receptor expression until later adulthood in rats-a possible model for schizophrenia. Behav Brain Res 205:96-101
2. Belforte JE, Zsiros V, Sklar ER, Jiang Z, Yu G, Li Y, Quinlan EM, Nakazawa K (2010) Postnatal NMDA receptor ablation in corticolimbic interneurons confers schizophrenia-like phenotypes. Nat Neurosci 13:76-83
3. Benes FM (2009) Neural circuitry models of schizophrenia: is it dopamine, GABA, glutamate, or something else? Biol Psychiatry 65:1003-1005
4. Bickel S, Javitt DC (2009) Neurophysiological and neurochemical animal models of schizophrenia: focus on glutamate. Behav Brain Res 204:352-362
5. Bitanihirwe BK, Lim MP, Kelley JF, Kaneko T, Woo TU (2009) Glutamatergic deficits and parvalbumin-containing inhibitory neurons in the prefrontal cortex in schizophrenia. BMC Psychiatry 9:71
6. Bortolozzi A, az-Mataix L, Toth M, Celada P, Artigas F, Bortolozzi A, az-Mataix L, Toth M, Celada P, Artigas F (2007) In vivo actions of aripiprazole on serotonergic and dopaminergic systems in rodent brain. Psychopharmacol 191:745-758 (Pubitemid 46355906)
7. Bowles TM, Levin GM (2003) Aripiprazole: a new atypical antipsychotic drug. Ann Pharmacother 37:687-694 (Pubitemid 36523066)
8. Bruins Slot LA, Kleven MS, Newman-Tancredi A (2005) Effects of novel antipsychotics with mixed D(2) antagonist/5-HT(1A) agonist properties on PCP-induced social interaction deficits in the rat. Neuropharmacolcology 49:996-1006 (Pubitemid 41503299)
9. Carlsson A (2006) The neurochemical circuitry of schizophrenia. Pharmacopsychiatry 39(Suppl 1):S10-S14 (Pubitemid 43357100)
10. Cheng MC, Liao D-L, Hsiung C-A, Chen C-Y, Liao Y-C, Chen C-H (2008) Chronic treatment with aripiprazole induces differential gene expression in the rat frontal cortex. Int J Neuropsychopharmacol 11:207-216 (Pubitemid 351231829)
11. Choi YK, Gardner MP, Tarazi FI (2009) Effects of risperidone on glutamate receptor subtypes in developing rat brain. Eur Neuropsychopharmacol 19:77-84
12. Corbett R, Camacho F, Woods AT, Kerman LL, Fishkin RJ, Brooks K, Dunn RW (1995) Antipsychotic agents antagonize noncompetitive N-methyl-D-aspartate antagonist-induced behaviors. Psychopharmacologia 120:67-74
13. Corlew R, Brasier DJ, Feldman DE, Philpot BD (2008) Presynaptic NMDA receptors: newly appreciated roles in cortical synaptic function and plasticity. Neuroscientist 14:609-625
14. Cosi C, Waget A, Rollet K, Tesori V, Newman-Tancredi A (2005) Clozapine, ziprasidone and aripiprazole but not haloperidol protect against kainic acid-induced lesion of the striatum in mice, in vivo: role of 5-HT1A receptor activation. Brain Res 1043:32-41 (Pubitemid 40603369)
15. Coyle JT, Tsai G, Goff D (2003) Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia. Ann NY Acad Sci 1003:318-327 (Pubitemid 38083065)
16. Dahan L, Husum H, Mnie-Filali O, Arnt J, Hertel P, Haddjeri N (2009) Effects of bifeprunox and aripiprazole on rat serotonin and dopamine neuronal activity and anxiolytic behaviour. J Psychopharmacol 23:177-189
17. Deng X, Shibata H, Takeuchi N, Rachi S, Sakai M, Ninomiya H, Iwata N, Ozaki N, Fukumaki Y (2007) Association study of polymorphisms in the glutamate transporter genes SLC1A1, SLC1A3, and SLC1A6 with schizophrenia. Am J Med Genet B Neuropsychiatr Genet 144B:271-278 (Pubitemid 46642014)
18. Du Bois TM, Deng C, Han M, Newell KA, Huang XF (2009) Excitatory and inhibitory neurotransmission is chronically altered following perinatal NMDA receptor blockade. Eur Neuropsychopharmacol 19:256-265
19. Duncan GE, Inada K, Farrington JS, Koller BH, Moy SS (2009) Neural activation deficits in a mouse genetic model of NMDA receptor hypofunction in tests of social aggression and swim stress. Brain Res 1265:186-195
20. El-Sayeh HG, Morganti C, Adams CE (2006) Aripiprazole for schizophrenia. Br J Psychiatry 189:102-108
21. Englisch S, Weinbrenner A, Inta D, Zink M (2009) Aripiprazole for the management of olanzapine-induced weight gain. Pharmacopsychiatry 42:166-167
22. Espinosa JS, Wheeler DG, Tsien RW, Luo L (2009) Uncoupling dendrite growth and patterning: single-cell knockout analysis of NMDA receptor 2B. Neuron 62:205-217
23. Farber NB (2003) The NMDA receptor hypofunction model of psychosis. Ann NY Acad Sci 1003:119-130 (Pubitemid 38083050)
24. Fejgin K, Safonov S, Palsson E, Wass C, Engel JA, Svensson L, Klamer D (2007) The atypical antipsychotic, aripiprazole, blocks phencyclidine-induced disruption of prepulse inhibition in mice. Psychopharmacologia 191:377-385 (Pubitemid 46354616)
25. Fitzgerald LW, Deutch AY, Gasic G, Heinemann SF, Nestler EJ (1995) Regulation of cortical and subcortical glutamate receptor subunit expression by antipsychotic drugs. J Neurosci 15:2453-2461
26. Funk AJ, Rumbaugh G, Harotunian V, McCullumsmith RE, Meador- Woodruff JH (2009) Decreased expression of NMDA receptorassociated proteins in frontal cortex of elderly patients with schizophrenia. Neuroreport 20:1019-1022
27. Gaspar PA, Bustamante ML, Silva H, Aboitiz F (2009) Molecular mechanisms underlying glutamatergic dysfunction in schizophrenia: therapeutic implications. J Neurochem 111:891-900
28. Gielen M, Retchless BS, Mony L, Johnson JW, Paoletti P (2009) Mechanism of differential control of NMDA receptor activity by NR2 subunits. Nature. doi:10.1038/nature07993
29. Gilmour G, Pioli EY, Dix SL, Smith JW, Conway MW, Jones WT, Loomis S, Mason R, Shahabi S, Tricklebank MD (2009) Diverse and often opposite behavioural effects of NMDA receptor antagonists in rats: implications for "NMDA antagonist modelling" of schizophrenia. Psychopharmacologia 205:203-216
30. Goebel DJ, Poosch MS (1999) NMDA receptor subunit gene expression in the rat brain: a quantitative analysis of endogenous mRNA levels of NR1Com, NR2A, NR2B, NR2C, NR2D and NR3A. Brain Res Mol Brain Res 69:164-170 (Pubitemid 29253809)
31. Goff DC, Coyle JT (2001) The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry 158:1367-1377 (Pubitemid 32847232)
32. Gonzalez-Burgos G, Lewis DA (2008) GABA neurons and the mechanisms of network oscillations: implications for understanding cortical dysfunction in schizophrenia. Schizophr Bull 34:944-961
33. Gordon JA (2010) Testing the glutamate hypothesis of schizophrenia. Nat Neurosci 13:2-4
34. Guo C, Yang Y, Su Y, Si T (2010) Postnatal BDNF expression profiles in prefrontal cortex and hippocampus of a rat schizophrenia model induced by MK-801 administration. J Biomed Biotechnol 2010:783297
35. Han M, Huang XF, Deng C (2009) Aripiprazole differentially affects mesolimbic and nigrostriatal dopaminergic transmission: implications for long-term drug efficacy and low extrapyramidal side-effects. Int J Neuropsychopharmacol. doi:10.1017/S1461145709009948
36. Harrison PJ, Law AJ, Eastwood SL (2003) Glutamate receptors and transporters in the hippocampus in schizophrenia. Ann NY Acad Sci 1003:94-101 (Pubitemid 38083047)
37. Harrison PJ, Weinberger DR (2005) Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry 10:40-68 (Pubitemid 40139588)
38. Henderson DC, Fan X, Copeland PM, Sharma B, Borba C, Boxill R, Freudenreich O, Cather C, Evins A, Goff DC (2009) Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients. J Clin Psychopharmacol 29:165-169
39. Henn FA (1995) The NMDA-receptor as a site for pathogenesis. Arch Gen Psychiatry 52:1008-1010
40. Homayoun H, Moghaddam B (2008) Orbitofrontal cortex neurons as a common target for classic and glutamatergic antipsychotic drugs. Proc Nat Acad Sci USA 105:18041-18046
41. Homayoun H, Moghaddam B (2007) NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J Neurosci 27:11496-11500 (Pubitemid 350006886)
42. Ibrahim HM, Hogg AJ Jr, Healy DJ, Haroutunian V, Davis KL, Meador-Woodruff JH (2000) Ionotropic glutamate receptor binding and subunit mRNA expression in thalamic nuclei in schizophrenia. Am J Psychiatry 157:1811-1823
43. Inoue A, Seto M, Sugita S, Hide I, Hirose T, Koga N, Kikuchi T, Nakata Y (1998) Differential effects on D2 dopamine receptor and prolactin gene expression by haloperidol and aripiprazole in the rat pituitary. Mol Brain Res 2:285-292 (Pubitemid 28248045)
44. Jenkins TA, Harte MK, Reynolds GP (2010) Effect of subchronic phencyclidine administration on sucrose preference and hippocampal parvalbumin immunoreactivity in the rat. Neurosci Lett 471:144-147
45. Jordan S, Koprivica V, Dunn R, Tottori K, Kikuchi T, Altar CA (2004) In vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function. Eur J Pharmacol 483:45-53 (Pubitemid 38056603)
46. Kalinichev M, Rourke C, Daniels AJ, Grizzle MK, Britt CS, Ignar DM, Jones DN (2005) Characterisation of olanzapine-induced weight gain and effect of aripiprazole vs olanzapine on body weight and prolactin secretion in female rats. Psychopharmacol 182:220-231 (Pubitemid 41464615)
47. Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, Ali MW (2002) Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 63:763-771
48. Kargieman L, Santana N, Mengod G, Celada P, Artigas F (2007) Antipsychotic drugs reverse the disruption in prefrontal cortex function produced by NMDA receptor blockade with phencyclidine. P Natl Acad Sci USA 104:14843-14848 (Pubitemid 350003230)
49. Kern RS, Green MF, Cornblatt BA, Owen JR, McQuade RD, Carson WH, Ali M, Marcus R (2006) The neurocognitive effects of aripiprazole: an open-label comparison with olanzapine. Psychopharmacol 187:312-320 (Pubitemid 44079923)
50. Konradi C, Heckers S (2003) Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment. Pharmaco Ther 97:153-179 (Pubitemid 36138820)
51. Kristiansen LV, Huerta I, Beneyto M, Meador-Woodruff JH (2007) NMDA receptors and schizophrenia. Curr Opin Pharmacol 7:48-55
52. Krystal JH, Perry EB Jr, Gueorguieva R, Belger A, Madonick SH, Bi-Dargham A, Cooper TB, Macdougall L, Bi-Saab W, D'Souza DC, Krystal JH, Perry EBJ, Gueorguieva R, Belger A, Madonick SH, Bi-Dargham A, Cooper TB, Macdougall L, Bi-Saab W, D'Souza DC (2005) Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function. Arch Gen Psychiatry 62:985-994
53. Lei G, Anastasio NC, Fu Y, Neugebauer V, Johnson KM (2009) Activation of dopamine D1 receptors blocks phencyclidineinduced neurotoxicity by enhancing N-methyl-D-aspartate receptor-mediated synaptic strength. J Neurochem 109:1017-1030
54. Leite JV, Guimaraes FS, Moreira FA (2008) Aripiprazole, an atypical antipsychotic, prevents the motor hyperactivity induced by psychotomimetics and psychostimulants in mice. Eur J Pharmacol 578:222-227 (Pubitemid 350309581)
55. Li M, Budin R, Fleming AS, Kapur S (2005) Effects of novel antipsychotics, amisulpiride and aripiprazole, on maternal behavior in rats. Psychopharmacol 181:600-610 (Pubitemid 41480910)
56. Li Z, Ichikawa J, Dai J, Meltzer HY (2004) Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain. Eur J Pharmacol 493:75-83 (Pubitemid 38746934)
57. Lieberman JA (2004) Dopamine partial agonists: a new class of antipsychotic. CNS Drugs 18:251-267 (Pubitemid 38393435)
58. Lopez-Gil X, Artigas F, Adell A (2009) Role of different monoamine receptors controlling MK-801-induced release of serotonin and glutamate in the medial prefrontal cortex: relevance for antipsychotic action. Int J Neuropsychopharmacol 12:487-499
59. Lopez-Gil X, Artigas F, Adell A (2010) Unraveling monoamine receptors involved in the action of typical and atypical antipsychotics on glutamatergic and serotonergic transmission in prefrontal cortex. Curr Pharm Des 16:502-515
60. MacDonald AW III, Chafee MV (2006) Translational and developmental perspective on N-methyl-D-aspartate synaptic deficits in schizophrenia. Dev Psychopathol 18:853-876 (Pubitemid 44445165)
61. McLean SL, Idris NF, Woolley ML, Neill JC (2009) D1-like receptor activation improves PCP-induced cognitive deficits in animal models: implications for mechanisms of improved cognitive function in schizophrenia. Eur Neuropsychopharmacol 19:440-450
62. Meyer-Lindenberg A, Weinberger DR (2006) Intermediate phenotypes and genetic mechanisms of psychiatric disorders. Nat Rev Neurosci 7:818-827 (Pubitemid 44435264)
63. Millan MJ (2005) N-Methyl-D-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives. Psychopharmacol 179:30-53 (Pubitemid 40576691)
64. Moghaddam B, Jackson ME (2003) Glutamatergic animal models of schizophrenia. Ann NY Acad Sci 1003:131-137 (Pubitemid 38083051)
65. Nagai T, Murai R, Matsui K, Kamei H, Noda Y, Furukawa H, Nabeshima T (2009) Aripiprazole ameliorates phencyclidineinduced impairment of recognition memory through dopamine D1 and serotonin 5-HT1A receptors. Psychopharmacol 202:315-328
66. Nordquist RE, Risterucci C, Moreau JL, von Kienlin M, Kunnecke B, Maco M, Freichel C, Riemer C, Spooren W (2008) Effects of aripiprazole/OPC-14597 on motor activity, pharmacological models of psychosis, and brain activity in rats. Neuropharmacol 54:405-416
67. Paoletti P, Neyton J (2007) NMDA receptor subunits: function and pharmacology. Curr Opin Pharmacol 7:39-47 (Pubitemid 46238036)
68. Patil ST, Zhang L, Martenyi F, Lowe SL, Jackson KA, Andreeev BV, Avedisova AS, Bardenstein LM, Gurovich IY, Morozova MA, Mosolov SN, Neznanov NG, Reznik AM, Smulevich AB, Tochilov VA, Johnson BG, Monn JA, Schoepp DD (2007) Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized phase 2 clinical trial. Nat Med 13:1102-1107 (Pubitemid 47517511)
69. Paxinos G, Watson C (1986) The rat brain in stereotaxic coordinates, 2nd edn. Academic, San Diego
70. Paz RD, Tardito S, Atzori M, Tseng KY (2008) Glutamatergic dysfunction in schizophrenia: from basic neuroscience to clinical psychopharmacology. Eur Neuropsychopharmacol 18:773-786
71. Potvin S, Stip E, Roy J-Y (2005) Toxic psychoses as pharmacological models of schizophrenia. Curr Psychiatry Rev 1:23-32
72. Rolls ET, Loh M, Deco G, Winterer G (2008) Computational models of schizophrenia and dopamine modulation in the prefrontal cortex. Nat Rev Neurosci 9:696-709
73. Roopun AK, Cunningham MO, Racca C, Alter K, Traub RD, Whittington MA (2008) Region-specific changes in gamma and beta2 rhythms in NMDA receptor dysfunction models of schizophrenia. Schizophr Bull 34:962-973
74. Schmitt A, Zink M, Mueller B, May B, Herb A, Jatzko A, Braus DF, Henn FA (2003a) Effects of long-term antipsychotic treatment on NMDA receptor binding and gene expression of subunits. Neurochem Res 28:235-241 (Pubitemid 36207348)
75. Schmitt A, Zink M, Petroianu G, May B, Braus DF, Henn FA (2003b) Decreased gene expression of glial and neuronal glutamate transporters after chronic antipsychotic treatment in rat brain. Neurosci Lett 347:81-84 (Pubitemid 36836221)
76. Segnitz N, Schmitt A, Gebicke-Härter P, Zink M (2009) Differential expression of glutamate transporter genes after chronic oral treatment with aripiprazole in rats. Neurochem Int 55:619-628
77. Seillier A, Giuffrida A (2009) Evaluation of NMDA receptor models of schizophrenia: Divergences in the behavioral effects of sub-chronic PCP and MK-801. Behav Brain Res 204:410-415
78. Semba J, Sakai M, Miyoshi R, Mataga N, Fukamauchi F, Kito S (1996) Differential expression of c-fos mRNA in rat prefrontal cortex, striatum, N. accumbens and lateral septum after typical and atypical antipsychotics: an in situ hybridization study. Neurochem Int 29:435-442 (Pubitemid 26297689)
79. Semba J, Watanabe A, Kito S, Toru M (1995) Behavioural and neurochemical effects of OPC-14597, a novel antipsychotic drug, on dopaminergic mechanisms in rat brain. Neuropharmacology 34:785-791
80. Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR, Roth BL, Mailman R (2003) Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacol 28:1400-1411 (Pubitemid 41070874)
81. Shim SS, Hammonds MD, Kee BS (2008) Potentiation of the NMDA receptor in the treatment of schizophrenia: focused on the glycine site. Eur Arch Psychiatry Clin Neurosci 258:16-27
82. Snigdha S, Horiguchi M, Huang M, Li Z, Shahid M, Neill JC, Meltzer HY (2010) Attenuation of phencyclidine-induced object recognition deficits by the combination of atypical antipsychotic drugs and pimavanserin (ACP 103), a 5-hydroxytryptamine(2A) receptor inverse agonist. J Pharmacol Exp Ther 332:622-631
83. Snigdha S, Neill JC (2008) Improvement of phencyclidine-induced social behaviour deficits in rats: involvement of 5-HT1A receptors. Beh Brain Res 191:26-31
84. Sparshatt A, Taylor D, Patel MX, Kapur S (2010) A systematic review of aripiprazole-dose, plasma concentration, receptor occupancy, and response: implications for therapeutic drug monitoring. J Clin Psychiatry 71:1447-1456
85. Squires RF, Saederup E (1991) A review of evidence for GABergic predominance/glutamatergic deficit as a common etiological factor in both schizophrenia and affective psychoses: more support for a continuum hypothesis of "functional" psychosis. Neurochem Res 16:1099-1111
86. Stephan KE, Friston KJ, Frith CD (2009) Dysconnection in schizophrenia: from abnormal synaptic plasticity to failures of self-monitoring. Schizophr Bull 35:509-527
87. Stone JM, Morrison PD, Pilowsky LS (2007) Review: glutamate and dopamine dysregulation in schizophrenia-a synthesis and selective review. J Psychopharmacol 21:440-452 (Pubitemid 47077295)
88. Tan HY, Chen Q, Sust S, Buckholtz JW, Meyers JD, Egan MF, Mattay VS, Meyer-Lindenberg A, Weinberger DR, Callicott JH (2007) Epistasis between catechol-O-methyltransferase and type II metabotropic glutamate receptor 3 genes on working memory brain function. Proc Nat Acad Sci USA 104:12536-12541 (Pubitemid 47206173)
89. Tarazi FI, Choi YK, Gardner M, Wong EH, Henry B, Shahid M (2009) Asenapine exerts distinctive regional effects on ionotropic glutamate receptor subtypes in rat brain. Synapse 63:413-420
90. Tran-Johnson TK, Sack DA, Marcus RN, Auby P, McQuade RD, Oren DA (2007) Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 68:111-119 (Pubitemid 46220132)
91. Ulas J, Nguyen L, Cotman CW (1993) Chronic haloperidol treatment enhances binding to NMDA receptors in rat cortex. Neuroreport 4:1049-1051 (Pubitemid 23242643)
92. Uylings HB, Van Eden CG (1990) Qualitative and quantitative comparison of the prefrontal cortex in rat and in primates, including humans. Progr Brain Res 85:31-62
93. Van Eden CG, Kros JM, Uylings HB (1990) The development of the rat prefrontal cortex. Its size and development of connections with thalamus, spinal cord and other cortical areas. Progr Brain Res 85:169-183
94. Van Eden CG, Rinkens A, Uylings HB (1998) Retrograde degeneration of thalamic neurons in the mediodorsal nucleus after neonatal and adult aspiration lesions of the medial prefrontal cortex in the rat. Implications for mechanisms of functional recovery. Eur J Neurosci 10:1581-1589
95. Van Eden CG, van Hest A, van Haaren F, Uylings HB (1994) Effects of neonatal mediodorsal thalamic lesions on structure and function of the rat prefrontal cortex. Brain Res Dev Brain Res 80:26-34 (Pubitemid 24228907)
96. Vrajova M, Stastny F, Horacek J et al (2010) Expression of the hippocampal NMDA receptor GluN1 subunit and its splicing isoforms in schizophrenia: postmortem study. Neurochem Res 35:994-1002
97. Walsh T, McClellan JM, McCarthy SE, Addington AM, Pierce SB, Cooper GM, Nord AS, Kusenda M, Malhotra D, Bhandari A, Stray SM, Rippey CF, Roccanova P, Makarov V, Lakshmi B, Findling RL, Sikich L, Stromberg T, Merriman B, Gogtay N, Butler P, Eckstrand K, Noory L, Gochman P, Long R, Chen Z, Davis S, Baker C, Eichler EE, Meltzer PS, Nelson SF, Singleton AB, Lee MK, Rapoport JL, King MC, Sebat J (2008) Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia. Science 320:539-543 (Pubitemid 351590668)
98. Wang HX, Gao WJ (2009) Cell type-specific development of NMDA receptors in the interneurons of rat prefrontal cortex. Neuropsychopharmacol 34:2028-2040
99. Wirkner K, Krause T, Koles L, Thummler S, Al-Khrasani M, Illes P (2004) D1 but not D2 dopamine receptors or adrenoceptors mediate dopamine-induced potentiation of N-methyl-d-aspartate currents in the rat prefrontal cortex. Neurosci Lett 372:89-93 (Pubitemid 39505234)
100. Wood MD, Scott C, Clarke K, Westaway J, Davies CH, Reavill C, Hill M, Rourke C, Newson M, Jones DN, Forbes IT, Gribble A, Wood MD, Scott C, Clarke K, Westaway J, Davies CH, Reavill C, Hill M, Rourke C, Newson M, Jones DNC, Forbes IT, Gribble A (2006) Aripiprazole and its human metabolite are partial agonists at the human dopamine D2 receptor, but the rodentmetabolite displays antagonist properties. Eur J Pharmacol 546:88-94 (Pubitemid 44339632)
101. Yamamura S, Ohoyama K, Hamaguchi T, Kashimoto K, Nakagawa M, Kanehara S, Suzuki D, Matsumoto T, Motomura E, Shiroyama T, Okada M (2009a) Effects of quetiapine on monoamine, GABA, and glutamate release in rat prefrontal cortex. Psychopharmacology 206:243-258
102. Yamamura S, Ohoyama K, Hamaguchi T, Nakagawa M, Suzuki D, Matsumoto T, Motomura E, Tanii H, Shiroyama T, Okada M (2009b) Effects of zotepine on extracellular levels of monoamine, GABA and glutamate in rat prefrontal cortex. Brit J Pharmacol 157:656-665
103. Yang TT, Wang SJ (2008) Aripiprazole and its human metabolite OPC14857 reduce, through a presynaptic mechanism, glutamate release in rat prefrontal cortex: possible relevance to neuroprotective interventions in schizophrenia. Synapse 62:804-818
104. Zilles K, Qu MS, Kohling R, Speckmann EJ (1999) Ionotropic glutamate and GABA receptors in human epileptic neocortical tissue: quantitative in vitro receptor autoradiography. Neurosci 94:1051-1061 (Pubitemid 29509672)
105. Zilles K, Werner L, Qu M, Schleicher A, Gross G (1991) Quantitative autoradiography of 11 different transmitter binding sites in the basal forebrain region of the rat-evidence of heterogeneity in distribution patterns. Neurosci 42:473-481
106. Zink M, Rapp S, Gebicke-Härter P, Henn FA, Thome J (2005) Antidepressants differentially affect expression of complexin I and II RNA in rat hippocampus. Psychopharmacol 181:560-565 (Pubitemid 41480905)